Highlights
- Circulating tumor DNA (ctDNA) is increasingly validated as a biomarker to guide adjuvant therapy decisions across multiple solid tumors.
- Recent prospective studies and trials demonstrate that ctDNA-guided strategies can personalize adjuvant treatment, potentially reducing overtreatment and improving outcomes.
- Technological advances in ctDNA detection and quantification provide enhanced sensitivity for minimal residual disease detection, enabling earlier intervention.
- Challenges remain in standardization, optimal timing, and integration into clinical guidelines, warranting further large-scale randomized studies.
Background
Specialty calculators
For clinical reference; use professional judgment.
